Please assess the completion status of the following clinical trial:

Trial Title: OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects aged 18 or older, male or female of any race with the diagnosis of NDPH meeting International Classification of Headache Disorders (ICHD-2) criteria will be included in the study. The criteria is as follows:~A. Persistent headache fulfilling criteria B and C B. Distinct and clearly remembered onset, with pain becoming continuous and unremitting within 24 hours C. Present for \>3 months D. Not better accounted for by another ICHD-3 diagnosis~Exclusion Criteria:~1. Those with relevant physical or psychological illness, particularly conditions that might put them at risk if exposed to OnabotulinumtoxinA (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other neuromuscular disease).~2. Diagnosis of other primary/secondary headache disorder.~3. Psychiatric disorders that could interfere with study participation.~4. Subjects who abuse drugs, including headache treatments and alcohol (DSM IV criteria).~5. Those allergic to compounds similar to the study medication.~6. Those who are pregnant or breastfeeding, or who do not use adequate contraceptive methods.~7. Those who have had any prior exposure to any botulinum toxin serotype.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OnabotulinumtoxinA (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).